PharmaTelevision - American Gene Technologies: the first bio-safe gene delivery vector for human clinical therapeutic use

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: American Gene Technologies: the first bio-safe gene delivery vector for human clinical therapeutic use

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Jeff Galvin, Chief Executive Officer at American Gene Technologies, a genetic research firm focusing on gene therapies for cancer

They discuss:

• the origins of American Gene Technologies
• targeting cancers with gene therapy as a priority
• types of viral vectors and their immune responses
• acquiring funding for research and human trials
• the risks of pursuing solely gene technologies as opposed to diversifying
• accuracy of targeting through specialisation

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The origins of American Gene Technologies.

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in San Francisco at BioPharm America. On this show I have Jeff Galvin, who is CEO of American Gene Technologies based in Rockfield, Maryland. Welcome to the show.

Jeff Galvin:

Thank you.

Fintan Walton:

Jeff Galvinas I said American Gene Technologies is a US based company, you've got offices both in the East Coast as well as the West Coast. What is a company like American Gene Technologies doing and in particular what is it doing in gene therapy?

Jeff Galvin:

Well our initial technology is a platform technology for gene delivery and what we've done is we've taken a step forward on the viral vectors, we use a lentiviral based system which can deliver multiple genes in vivo and we are testing right now, but we believe it's safe for clinical use.

Fintan Walton:

When was the company founded and tell me about that?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jeff Galvin

Chief Executive Officer

Jeff Galvin, is the Chief Executive Officer of American Gene Technologies a genetic research firm focusing on gene therapies for cancer.

American Gene Technologies

American Gene Technologies is developing genetic therapies and cures which address multi-billion dollar markets in healthcare. Its technology is at the heart of genetic research and the development activities of major biopharma companies. American Gene Technologiesis actively pursuing collaborations with industry and government to characterize and cure hundreds of genetic diseases.